论文部分内容阅读
乙性肝炎病毒感染所导致的慢性肝炎是我国的一个大问题,给患者及社会带来了很大负担。慢性乙型肝炎现行治疗主要依靠干扰素、核苷类似物等,其存在高耐药、低耐受以及不良反应等问题。新的、更为安全有效的治疗药物及方法亟待发展。最近,科学家们发现人体内的TRIM22分子对抑制乙肝病毒的复制起到重要作用,为乙肝的治疗及有效药物的研发开辟了新的道路。
Chronic hepatitis caused by hepatitis B virus infection is a big problem in our country, which brings a great burden to patients and society. The current treatment of chronic hepatitis B relies mainly on interferons, nucleoside analogs, etc., which have high resistance, low tolerance and adverse reactions and other issues. New, safer and more effective treatments and methods are in urgent need of development. Recently, scientists found that human TRIM22 molecules play an important role in inhibiting the replication of hepatitis B virus, opening up a new path for the treatment of hepatitis B and the development of effective drugs.